KEROS THERAPEUTICS INC

Insider buying signals renewed optimism for KEROS Therapeutics – owner Seth Alpna’s new RSUs and options show confidence in the company’s pipeline and potential upside.

Alpna’s 2026‑06‑04 sale of 2,625 KEROS shares shows insider confidence amid a spike in social‑media buzz, highlighting potential shifts in strategy and liquidity needs.

Insightful insider buying by Keros Therapeutics’ CEO signals potential upcoming clinical or partnership milestones that could boost shareholder value amid volatile biotech markets.

Insider sales at Keros Therapeutics are routine sell‑to‑cover moves for tax‑withholding, not a signal of panic—investors should watch clinical milestones and funding rounds for real impact.